Recent News

• 05.11.2026 - Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101
• 05.06.2026 - Ernexa Therapeutics Unveils Breakthrough Preclinical Results: ERNA-101 Achieves 100% Survival and Complete Tumor Elimination in Ovarian Cancer Models
• 04.30.2026 - Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split
• 03.31.2026 - Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026
• 02.20.2026 - Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series

Recent Filings

• 05.04.2026 - 8-K Current report
• 04.13.2026 - DEF 14C Other definitive information statements
• 04.01.2026 - PRE 14C Other preliminary information statements
• 03.30.2026 - EFFECT Notice of Effectiveness
• 03.26.2026 - CORRESP Correspondence
• 03.24.2026 - S-3/A Registration statement under Securities Act of 1933
• 03.20.2026 - UPLOAD SEC-generated letter
• 03.20.2026 - 8-K Current report
• 03.16.2026 - S-3 Registration statement under Securities Act of 1933
• 03.13.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]